| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology |
Lady Davis Research Institute of the Sir Mortimer B. Davis Jewish General Hospital and Departments of Oncology and Medicine, McGill University, Montreal, Quebec, H3T 1E2 Canada [T. N., M. P.], and Division of Urology, Vancouver General Hospital, University of British Columbia, British Columbia, V5Z 3J5 Canada [H. M., M. E. G.]
Insulin-like growth factor (IGF) I has well-characterized mitogenic and antiapoptotic effects that are essential for maintenance of the normal prostate and may be important during regression of the normal prostate and/or prostate tumors induced by androgen-targeting therapies for prostate cancer. IGF-I activity is modulated by IGF-binding proteins (IGFBPs). Here we examine IGFBP expression during regression of androgen-dependent Shionogi carcinoma tumors after castration. In this model, we observe a 90% reduction in Shionogi tumors by 10 days postcastration. Northern blotting of RNA from tumors collected at various times after castration indicates a rapid induction of IGFBP-5 concomitant with apoptotic regression of tumors, as detected by Apoptag staining of tumor sections after castration. IGFBP-5 mRNA was not detectable in tumors from control animals, but levels increased 120-fold in tumors 3 days after castration. The mRNAs for IGFBP-3 and -4 were abundant in Shionogi tumors from intact mice and decreased to
33% and
20% of control, respectively. Castration had no significant effect on IGFBP-2 expression. Treatment with calcium channel blockers inhibited castration-induced apoptosis and tumor regression and also significantly inhibited up-regulation of IGFBP-5 after castration. These data provide strong evidence for a functional role of IGFBP-5 expression in mediating the apoptosis induced by androgen deprivation in androgen-dependent neoplasia.
This article has been cited by other articles:
![]() |
S. R. Plymate, K. Haugk, I. Coleman, L. Woodke, R. Vessella, P. Nelson, R. B. Montgomery, D. L. Ludwig, and J. D. Wu An Antibody Targeting the Type I Insulin-like Growth Factor Receptor Enhances the Castration-Induced Response in Androgen-Dependent Prostate Cancer Clin. Cancer Res., November 1, 2007; 13(21): 6429 - 6439. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Kleinberg, W. Ruan, D. Yee, K. T. Kovacs, and S. Vidal Insulin-Like Growth Factor (IGF)-I Controls Prostate Fibromuscular Development: IGF-I Inhibition Prevents Both Fibromuscular and Glandular Development in Eugonadal Mice Endocrinology, March 1, 2007; 148(3): 1080 - 1088. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Seenundun and B. Robaire Time-Dependent Rescue of Gene Expression by Androgens in the Mouse Proximal Caput Epididymidis-1 Cell Line after Androgen Withdrawal Endocrinology, January 1, 2007; 148(1): 173 - 188. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. GLEAVE and K. N. CHI Knock-down of the Cytoprotective Gene, Clusterin, to Enhance Hormone and Chemosensitivity in Prostate and Other Cancers Ann. N.Y. Acad. Sci., November 1, 2005; 1058(1): 1 - 15. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. GLEAVE and B. JANSEN Clusterin and IGFBPs as Antisense Targets in Prostate Cancer Ann. N.Y. Acad. Sci., December 1, 2003; 1002(1): 95 - 104. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kiyama, K. Morrison, T. Zellweger, M. Akbari, M. Cox, D. Yu, H. Miyake, and M. E. Gleave Castration-Induced Increases in Insulin-Like Growth Factor-Binding Protein 2 Promotes Proliferation of Androgen-independent Human Prostate LNCaP Tumors Cancer Res., July 1, 2003; 63(13): 3575 - 3584. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Firth and R. C. Baxter Cellular Actions of the Insulin-Like Growth Factor Binding Proteins Endocr. Rev., December 1, 2002; 23(6): 824 - 854. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. W. Elmlinger, I. Mayer, D. Schnabel, B. S. Schuett, D. Diesing, G. Romalo, H. A. Wollmann, W. Weidemann, K.-D. Spindler, M. B. Ranke, et al. Decreased Expression of IGF-II and Its Binding Protein, IGF-Binding Protein-2, in Genital Skin Fibroblasts of Patients with Complete Androgen Insensitivity Syndrome Compared with Normally Virilized Males J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4741 - 4746. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nickerson, F. Chang, D. Lorimer, S. P. Smeekens, C. L. Sawyers, and M. Pollak In Vivo Progression of LAPC-9 and LNCaP Prostate Cancer Models to Androgen Independence Is Associated with Increased Expression of Insulin-like Growth Factor I (IGF-I) and IGF-I Receptor (IGF-IR) Cancer Res., August 1, 2001; 61(16): 6276 - 6280. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Chokkalingam, M. Pollak, C.-M. Fillmore, Y.-T. Gao, F. Z. Stanczyk, J. Deng, I. A. Sesterhenn, F. K. Mostofi, T. R. Fears, M. P. Madigan, et al. Insulin-like Growth Factors and Prostate Cancer: A Population-based Case-Control Study in China Cancer Epidemiol. Biomarkers Prev., May 1, 2001; 10(5): 421 - 427. [Abstract] [Full Text] |
||||
![]() |
H. M. Khandwala, I. E. McCutcheon, A. Flyvbjerg, and K. E. Friend The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth Endocr. Rev., June 1, 2000; 21(3): 215 - 244. [Abstract] [Full Text] |
||||
![]() |
H. Miyake, C. Nelson, P. S. Rennie, and M. E. Gleave Overexpression of Insulin-Like Growth Factor Binding Protein-5 Helps Accelerate Progression to Androgen-Independence in the Human Prostate LNCaP Tumor Model through Activation of Phosphatidylinositol 3'-Kinase Pathway Endocrinology, June 1, 2000; 141(6): 2257 - 2265. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Miyake, M. Pollak, and M. E. Gleave Castration-induced Up-Regulation of Insulin-like Growth Factor Binding Protein-5 Potentiates Insulin-like Growth Factor-I Activity and Accelerates Progression to Androgen Independence in Prostate Cancer Models Cancer Res., June 1, 2000; 60(11): 3058 - 3064. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Miyake, C. Nelson, P. S. Rennie, and M. E. Gleave Testosterone-repressed Prostate Message-2 Is an Antiapoptotic Gene Involved in Progression to Androgen Independence in Prostate Cancer Cancer Res., January 1, 2000; 60(1): 170 - 176. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |